Invitation for Expression of Interest for Validation of Rapid Antigen Detection Assays for COVID-19:

Context:

As India is lifting lockdowns in various parts of the country in a phased manner, it is expected to see an upsurge in cases of COVID-19 due to increased transmission of SARS-CoV-2 virus. In view of this, it is important to scale up testing capacity to the maximum possible levels.

The gold standard RT-PCR diagnostic test for COVID-19 has limitations in terms of widespread availability. In view of this, there is urgent requirement of reliable and convenient rapid point of care antigen detection assays with high sensitivity and specificity. Such assays could be used as potential diagnostic tests in all possible public and private healthcare settings and made available for mass testing.

So far, ICMR has validated and approved three rapid antigen detection assays.

ICMR invites applications for validation of rapid antigen detection tests for COVID-19 from all manufacturers who have developed such test.

ICMR has identified the following sites for validation of the rapid point-of-care antigen detection tests for COVID-19:

1. All India Institute of Medical Sciences, Delhi
2. SMS Medical College, Jaipur
3. King George Medical University, Lucknow
4. Kasturba Hospital for Infectious Diseases, Mumbai
5. Post Graduate Institute of Medical Education & Research, Chandigarh
6. Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry
7. National Institute of Virology, Kerala Unit, Alappuzha
8. Bangalore Medical College & Research Institute, Bengaluru
9. National Institute of Mental Health and Neurosciences, Bengaluru
10. All India Institute of Medical Sciences, Bhopal
11. All India Institute of Medical Sciences, Raipur
12. All India Institute of Medical Sciences, Jodhpur
13. B J Medical College, Ahmedabad
14. Kings Institute for Preventive Medicine & Research, Chennai
15. Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram
Essential criteria for validation:

1. A minimum of 300 rapid antigen tests from three different batches (100 from each batch) would be required for each validation.
2. A minimum of 3-4 instruments (if the test results are to be interpreted using a specialized equipment such as fluorescence immunoassay readers etc.) will be required.
3. Ability to provide training to technical staff involved in validation of the test.
4. If the kit is approved after validation, the manufacturers should be committed to make adequate supplies of the product available to India with immediate effect.
5. Import / test license from CDSCO/DCGI wherever applicable.

All interested manufacturers fulfilling the above essential criteria are requested to send their applications to the following email id:

guptanivedita.hq@icmr.gov.in

Subject-line of the email should read as: REQUEST FOR VALIDATION OF COVID-19 RAPID ANTIGEN TEST.